 |
|
|
| |
2 year outcomes of dolutegravir/rilpivirine in virologically suppressed
HIV-infected PLHIV: Real-world data from the German JUNGLE cohort
|
| |
| |
EACS 2021 Oct 27-30
Kevin Ummard-Berger1, Christoph Wyen2, Farhad Schabaz3, Heribert Hillenbrand4, Daniel Beer5, Stephan Schneeweiss6, Gordon Weinberg7, Nils Postel8, Bernd Westermayer9, Kathrin Maria Dymek10, Jenny Scherzer10
1UBN/Praxis, Berlin, Germany; 2Praxis Ebertplatz Cologne, Germany; 3MVZ München am Goetheplatz, Munich, Germany; 4MVZ PraxisCityOst, Berlin, Germany; 5Praxis Dr. Knechten Aachen, Germany; 6Praxis Hohenstaufenring, Cologne, Germany; 7Infektiologisches Zentrum Steglitz, Berlin, Germany; 8prinzmed, Munich, Germany; 9GlaxoSmithKline Munich, Germany; 10ViiV Healthcare, Munich, Germany
|
| |
|
|
|
|
|
